Intelligent Ultrasound Regulatory News (IUG)

Intelligent Ultrasound Group plc

(the "Group" or the "Company" or "Intelligent Ultrasound")

Results of General Meeting and Total Voting Rights

Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic' ultrasound company, specialising in artificial intelligence (AI) software and simulation, announces that at the General Meeting held earlier today, all resolutions proposed were duly passed on a poll by shareholders. A summary of the voting results is shown below:

* This column represents the number of votes that were cast for the resolutions as a percentage of the number of votes cast in total for each resolution either in person or by proxy.

Accordingly, the Company will raise a total of £5.2 million (before expenses) via a Placing and Subscription through the issue and allotment of 56,216,220 new Ordinary Shares. An application has been made for the 27,028,752 EIS/VCT Placing Shares to be admitted to trading on AIM, which is expected to take place at 8.00 a.m. on 1 December 2022. A further application has been made for the 15,475,360 General Placing Shares and 13,712,108 Subscription Shares to be admitted to trading on AIM, which is expected to take place at 8.00 a.m. on 2 December 2022.

Following admission of both the EIS/VCT Placing Shares, the General Placing Shares and the Subscription Shares, the Company's issued share capital of 326,869,705 will comprise Ordinary Shares, of which none are held in treasury. The above figure of may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the voting rights of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the circular sent to shareholders of the Company on 11 November 2022.

Enquiries:

About Intelligent Ultrasound Group

Intelligent Ultrasound (AIM: IUG) is one of the world's leading 'classroom to clinic' ultrasound companies, specialising in real-time hi-fidelity virtual reality simulation for the ultrasound training market ('classroom') and artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market ('clinic'). Based in Cardiff in the UK and Atlanta in the US, the Group has two revenue streams:

Simulation

Real-time hi-fidelity ultrasound education and training through simulation. Our main products are the ScanTrainer obstetrics and gynaecology training simulator, the HeartWorks echocardiography training simulator, the BodyWorks Eve Point of Care and Emergency Medicine training simulator with Covid-19 module and the new BabyWorks Neonate and Paediatric training simulator. To date over 1,400 simulators have been sold to c. 700 medical institutions around the world.

Clinical AI software

Deep learning-based algorithms to make ultrasound machines smarter and more accessible using our proprietary ScanNav ultrasound image analysis technology. Current products on the market utilising this technology are GE Healthcare's SonoLyst software that is incorporated in their Voluson Expert 22 and SWIFT ultrasound machines; ScanNav Anatomy PNB that simplifies ultrasound-guided needling by providing the user with real-time AI-based anatomy highlighting for a range of medical procedures; and NeedleTrainer that teaches real-time ultrasound-guided needling and incorporates ScanNav Anatomy PNB. 

www.intelligentultrasound.com